A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of BGB 21447 in Patients With Mature B-Cell Malignancies

The primary objective of this phase 1/1b study is to evaluate the safety and dose-escalation profile of the Bcl-2 inhibitor BGB 21447 in patients diagnosed with mature B-cell malignancies. This investigation is clinically significant for establishing the tolerable dose range and determining the optimal dose for subsequent therapeutic applications. No secondary objectives were specified.

This clinical trial involves 192 patients diagnosed with mature B-cell malignancies. The study population comprises both male and female individuals. Based on the provided age range codes, the participants belong to specific age cohorts. The sponsor did not provide additional information regarding lifestyle considerations or specific selection methodologies.

This is a Phase 1/1b, open-label, dose-escalation and dose-optimization study evaluating the Bcl-2 inhibitor BGB 21447 in patients diagnosed with mature B-cell malignancies. The research methodology involves determining the appropriate dosage through sequential escalation and optimization phases. The clinical trial sequence begins with a screening visit to assess eligibility. Subsequent study visits will involve monitoring the effects of the investigational product, concluding with an end-of-study visit. The total duration of the clinical trial is estimated to span from November 2025 to November 2027.

The assessment of efficacy in this clinical trial focuses on the management of mature B-cell malignancies. The evaluation process is designed to monitor therapeutic responses according to the clinical objectives of the study protocol.